HDACis/Hsp90 inhibitors, PI3K/mTOR inhibitors, PIM kinase inhibitors, and MEK inhibitors target JAK2V617F or down-stream signaling molecules

HDACis/Hsp90 inhibitors, PI3K/mTOR inhibitors, PIM kinase inhibitors, and MEK inhibitors target JAK2V617F or down-stream signaling molecules

Client: Haematologica

Figure for the reviewAdvances in myelofibrosis: a clinical case approach published in the October edition (2013) of Haematologica. It shows that HDACis/Hsp90 inhibitors, PI3K/mTOR inhibitors, PIM kinase inhibitors, and MEK inhibitors target JAK2V617F or down-stream signaling molecules.

By |October 21st, 2013|Syndicated Content|

About the Author: